Final guidance issued by FDA for IDE benefits and risks

By Stewart Eisenhart, Emergo Group

Final guidance from the US Food and Drug Administration lays out key factors the agency uses to assess benefits and risks of Investigational Device Exemption (IDE) applications for medical device clinical trials.

Get the full story here at the Emergo Group’s blog.

The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.

The post Final guidance issued by FDA for IDE benefits and risks appeared first on MassDevice.

from MassDevice http://ift.tt/2iHRkvq